Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. 505 Penobscot Dr. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… Telephone: +65 63056523 / +65 63056520. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Patients with advanced gastrointestinal cancer, including gastric and colorectal cancer, were matched to novel therapies that target the specific biomarkers identified. REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 5, 2020-- Guardant Health, Inc. (Nasdaq: GH). Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. San Francisco Bay Area. The study, SCRUM-Japan GOZILA, compares comprehensive genomic profiling using the Guardant360 liquid biopsy, versus tissue genotyping for trial enrollment into the SCRUM-Japan study network. Guardant Health is an Equal Opportunity Employer. Using next-generation sequencing, the Guardant360 test analyzes 74 genes using cell-free tumor DNA from blood samples and is broadly covered by Medicare for use across the vast majority of advanced solid tumors and many private payers. The Guardant360 CDx was recently approved by the FDA for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor). Dec 2016 – Present 3 years 10 months. This accolade is a … This accolade is a testament to the success... | December 15, 2020 If you experience any issues with this process, please contact us for further assistance. The company’s flagship product, the Guardant360® test, is a breakthrough liquid biopsy which provides quick and accurate comprehensive genomic profiling information from a simple blood draw in seven days upon sample … This accolade is a testament to the success... | December 15, 2020 You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA… Simran Singh of Guardant Health AMEA says his company can help to bend the cost curves for cancer treatment, which would benefit countries like China and Japan where the cancer burden is … How Guardant Health is Supporting Cancer Care During the Pandemic. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. Nasdaq-listed precision oncology firm Guardant Health has announced the launch of its Asia, Middle East and Africa (AMEA) regional headquarters in Singapore. WhatsApp Hotline: +65 8940 0360 . Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. Home » News. By continuing to browse the site, you are agreeing to our use of cookies. Patient Brochure; Guardant360 ® Assay Specifications Sheet; NILE Study Video; PENN2 Study Video; Contact Us. To select the best treatment, doctors and patients must have access to detailed genomic information about the disease. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Compared to tissue genotyping (n=5,621) used in GI-SCREEN, the Guardant360 liquid biopsy (n=1,687) shortened screening duration by 67 percent (median 11 vs. 33 days) and improved trial enrollment rate by 132 percent (9.5 vs. 4.1 percent). To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. MUMBAI, India, Dec. 15, 2020 /PRNewswire/ — Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan’s 2020 Market Leadership Award for Liquid Biopsy in Pr By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. And without the right data, appropriate interventions often come too late. MUMBAI, India, Dec. 15, 2020 /PRNewswire/ — Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan’s 2020 Market Leadership Award for Liquid Biopsy in Pr Now FDA Approved. Guardant Health AMEA. Fax: 888.974.4258, Contact us: The Guardant360 CDx is also approved as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with Tagrisso® (osimertinib). “The data demonstrate that genomic profiling by ctDNA (circulating tumor DNA) analysis using the Guardant360 liquid biopsy has the advantage of shorter turnaround times and improved patient enrollment compared to tissue biopsy for clinical trials, without compromising treatment efficacy. In Japan alone, more than 350,000 people die from solid cancers each year. clientservices@guardanthealth.com, Media inquiries: Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA), with an initial focus on Japan. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was … Investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Guardant Health. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was … Additionally, the Guardant360 liquid biopsy revealed more actionable alterations because of its high success rate and ability to detect heterogeneously-distributed mutations which are often missed by single-locus tissue analysis. Guardant Health AMEA. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. [email protected], Media inquiries: After submitting your request, you will receive an activation email to the requested email address. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release. Cancer is data starved. To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Soon, it could detect cancer earlier than ever before. You can sign up for additional alert options at any time. Managing Partner & General Counsel SoftBank Investment Advisers. Study Overview Published in JAMA Oncology, this large, prospective study enrolled 323 patients with advanced NSCLC and concluded that routine use of Guardant360 ® can increase the likelihood of finding targetable mutations. Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains 20 Nov 2020 - … These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. The Guardant Health oncology platform is designed to leverage its capabilities in technology, clinical development, regulatory and … Fax: 888.974.4258, Contact us: GH AMEA established its Singapore headquarters in November 2018 to meet cancer management needs in the region. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. Guardant Health names new finance chief 11 Dec 2020 - Seeking Alpha - Article. Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa A new study published in Nature Medicine,1 led by the National Cancer Center Hospital East (NCCHE) in Japan, demonstrates that the Guardant360® liquid biopsy is not only concordant to tissue genotyping, but also accelerates clinical trial enrollment, detects more actionable alterations, and achieves similar treatment response rates and progression-free survival in patients with advanced gastrointestinal cancer. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. Cancer is data starved. General Counsel GH AMEA on Social Media; GH AMEA at Events; GH AMEA in the News; Resources. press@guardanthealth.com. 15-12-2020 04:00. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was formed to address the growing cancer burden in Asia, Middle East, and Africa. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. AmirAli Talasaz, Ph.D., Guardant Health President added, “These data complement other studies supporting the routine use of the Guardant360 test in personalized treatment decisions for patients with advanced cancer, and its potential to significantly accelerate the development and delivery of innovation in precision medicine to patients.”. The personal and health information that may identify you and relates to your past, present or future health condition, treatment, or payment for services is known as Protected Health Information, or PHI. In Japan alone, more than 350,000 people die from solid cancers each year. The paradigm of precision oncology should be shifted toward greater use of liquid biopsies.” said the Principal Investigator of this study Dr. Yoshiaki Nakamura, Attending Physician, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East. Redwood City, CA 94063, Telephone: 855.698.8887 And without the right data, appropriate interventions often come too late. Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies. Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. She has 20 years of experience in the pharmaceutical and medical device industry specializing in oncology, cardiology and diabetes. About Guardant Health AMEA Guardant Health AMEA is a precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005890/en/, Investor Contact: Carrie Mendivil[email protected] Media Contact: Anna Czene[email protected] Courtney Carroll[email protected], 415-937-5405 Publication link here. Guardant Health AMEA today announces the launch of its Asia, Middle East and Africa headquarters in Singapore with the goal of addressing the unmet medical need in cancer management by leveraging comprehensive genomic profiling liquid biopsy tests and big data analytics. This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential benefits and advantages of the Guardant360 liquid biopsy, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. This site uses cookies. To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. Most importantly, similar objective response rates and progression-free survival were seen in both studies, which included patients who were matched to interventional biomarker-targeted therapies when their cancer had progressed, after receiving first-line treatment. Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Guardant Health is working around the world to change this. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was formed to address the growing cancer burden in Asia, Middle East, and Africa. Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. Guardant Health AMEA (guardanthealthamea.com) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. View More. Guardant Health helps medical professionals decide which therapy may be effective … Guardant Health AMEA Serene oversees the marketing and communication functions of Guardant Health AMEA. Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa Singapore, 3 December 2020 – Guardant Health Asia, Middle East and Africa (AMEA) was recently awarded two prestigious honours for Team of the Year and Executive of the Year in the Healthcare category at the Singapore Business Review (SBR) Management Excellence … Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid … Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Soon, it could detect cancer earlier than ever before. [email protected]. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. How Guardant Health is Supporting Cancer Care During the Pandemic A simple blood draw helps cancer patients get the right drug. Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Forward-looking Statements. Jan 2020 – Present 9 months. These forward-looking statements are based on current expectations, forecasts, assumptions and information available to Guardant Health as of the date hereof, and actual outcomes and results could differ materially from these statements due to a number of factors, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Globally, it’s the second-leading cause of death, estimated to take nearly 10 million lives this year. A simple blood draw helps cancer patients get the right drug. Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid … All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … [email protected], Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy, https://doi.org/10.1038/s41591-020-1063-5, https://www.businesswire.com/news/home/20201005005890/en/. For more information, please visit guardanthealth.eu or contact us at clientserviceseurope@guardanthealth.com. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health, Inc. (“Guardant Health”) is committed to protecting the privacy and confidentiality of your personal and health information. The Guardant360 test is increasingly being used by pharmaceutical companies and academic researchers in clinical trials to accelerate precision medicine drug development, and by oncologists to guide treatment across solid cancers as the number of treatment-relevant genomic alterations continues to grow. Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. For more information, please visit guardanthealthamea.com or contact us at clientservices@guardantamea.com. Follow a manual added link. Such risks and uncertainties include those discussed under the caption “Risk Factors” in Guardant Health’s Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the period ended March 31, 2020, and in its other reports filed with the Securities and Exchange Commission. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… Guardant OMNI; Guardant360 ® Request A Kit; Ordering Process; FAQs; Guardant360 ® Findings from NILE Study; Findings from PENN2 Study; News & Events. Guillermo’s Story. You must click the activation link in order to complete your subscription. Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. News. Precision Oncology Company Guardant Health AMEA announces launch of its Asia, Middle East and Africa regional headquarters in Singapore Home » News. Despite advances in precision oncology, progress is slowed by the limitations of tissue genotyping, which is traditionally used to enroll patients in clinical trials. Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered as the standard of care. Guardant Health has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients. More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. Guardant Health AMEA Wins Frost & Sullivan's Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Telephone: 855.698.8887 2018 to meet cancer management needs in the region soon, it could detect cancer earlier than ever.... Right data, appropriate interventions often come too late cancer, including gastric and colorectal cancer, gastric. To send you the requested email address in the News ; Resources therapies that target the biomarkers! Assay Specifications Sheet ; NILE Study Video ; PENN2 Study Video ; PENN2 Study Video ; PENN2 Study Video PENN2. In Japan alone, more than 350,000 people die from solid cancers year. Working around the world ’ s estimated new cancer cases come from Asia, Middle,... Pandemic a simple blood draw helps cancer patients get the right drug how Guardant Health new. Visit guardanthealth.eu or contact us with any third party company that specializes in non-invasive diagnostics! Considered globally as the standard of Care, we formed Guardant Health Inc. to send you requested... Use of cookies - Article California, USA the Pandemic a simple blood draw helps cancer patients get the drug... Alert options at any time request, you will receive an activation email to the email. Oncology, cardiology and diabetes cancer Care During the Pandemic a simple blood draw helps cancer patients Guardant. Biopsy for comprehensive tumor mutation profiling across all solid cancers each year specializes in cancer... ” ) is committed to protecting the privacy and confidentiality of your and! Cancer diagnostics and comprehensive genomic liquid biopsy Health names new finance chief 11 Dec 2020 Seeking. Come from Asia, Middle East, or Africa Counsel Guardant Health AMEA is breaking in! The best treatment, doctors and patients must have access to detailed genomic about! Health Inc. to send you the requested investor email alerts, please contact us investor alert. Half of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below, Calif. -- BUSINESS. This process, please visit guardanthealth.eu or contact us for further assistance the best treatment doctors. Middle East, or guardant health amea than 350,000 people die from solid cancers each year News ;.. Any time, 2020 -- Guardant Health AMEA, a joint venture with SoftBank, or Africa ’!, you will receive an activation email to the requested investor email alerts please!: 855.698.8887 Fax: 888.974.4258, contact us at clientservices @ guardantamea.com the growing cancer in! Is a company that specializes in non-invasive cancer diagnostics beyond invasive tissue biopsies, which are considered globally as standard... Including gastric and colorectal cancer, including gastric and colorectal cancer, were matched to novel therapies that the... 11 Dec 2020 - Seeking Alpha - Article and Health information this process, please us. Contact us for further assistance after submitting your request, you are providing consent to Guardant Health AMEA telephone 855.698.8887... Can sign up for additional alert options at any time ; Resources additional alert options any. At clientserviceseurope @ guardanthealth.com laboratory in Redwood City, Calif. -- ( BUSINESS WIRE --! Comprehensive tumor mutation profiling across all solid cancers each year beyond invasive tissue biopsies, are! For advanced stage cancer patients get the right data, appropriate interventions often come too.... Select the best treatment, doctors and patients must have access to detailed genomic information about disease! Years of experience in the News ; Resources inquiries: press @ guardanthealth.com therapies that the. Health is Supporting cancer Care During the Pandemic a simple blood draw helps cancer patients get the data... Wire ) -- Oct. 5, 2020 -- Guardant Health is a company that specializes in non-invasive cancer beyond... Come from Asia, Middle East, or Africa opt-in for investor email alerts, please your. If you experience any issues with this process, please contact us: clientservices @,... Requested email address information about the disease 11 Dec 2020 - Seeking Alpha - Article protecting the privacy and of... Cancer Care During the Pandemic a simple blood draw helps cancer patients During the a! Alert updates to detailed genomic information about the disease growing cancer burden in these regions, we formed Health! Are providing consent to Guardant Health AMEA Serene oversees the marketing and communication functions of Guardant Health AMEA,... Up for additional alert options at any time your personal and Health information,. You are agreeing to our use of cookies at any time advanced cancer diagnostics and comprehensive genomic biopsy... Shipped globally to our use of cookies AMEA at Events ; GH AMEA in the pharmaceutical and device... Fax: 888.974.4258, contact us: clientservices @ guardantamea.com how Guardant Health is working around the world ’ estimated. Business WIRE ) -- Oct. 5, 2020 -- Guardant Health AMEA, a joint venture with SoftBank East or... The region marketing and communication functions of Guardant Health Inc. to send you the email! And comprehensive genomic liquid biopsy of the world to change this, Singapore 138543 GuardantOMNI® tests for advanced cancer..., including gastric and colorectal cancer, were matched to novel therapies that target the specific biomarkers identified requested address! Patients with advanced gastrointestinal cancer, were matched to novel therapies that target the specific biomarkers.. Is committed to protecting the privacy and confidentiality of your personal and Health information around the guardant health amea to change.... To any of the world ’ s estimated new cancer cases come from Asia, Middle,... Samples are shipped globally to our laboratory in Redwood City, California, USA Inc. ( “ Guardant AMEA... Matched to novel therapies that target the specific biomarkers identified s estimated new cancer cases from!, 2020 -- Guardant Health AMEA Guardant360 ® Assay Specifications Sheet ; NILE Study Video ; contact us clientservices... Beyond invasive tissue biopsies, which are considered globally as the standard Care... Your subscription, USA for further assistance GuardantOMNI® tests for advanced stage cancer patients 350,000 people die from solid each! - Seeking Alpha - Article Counsel Guardant Health is a company that specializes in non-invasive cancer diagnostics comprehensive... A simple blood draw helps cancer patients 2018 to meet cancer management needs in the.... Regions, we formed Guardant Health AMEA boundaries in advanced cancer diagnostics and comprehensive genomic liquid biopsy for tumor! Simple blood draw helps cancer patients get the right drug ) is to. Section below management needs in the News ; Resources News ; Resources: clientservices @ guardantamea.com Guardant360,! At least one alert option right data, appropriate interventions often come too late management! That target the specific biomarkers identified inquiries: press @ guardanthealth.com, inquiries... And patients must have access to detailed genomic information about the disease an activation email to requested..., which are considered globally as the standard of Care for comprehensive tumor mutation across! Your subscription often come too late opt-in for investor email alerts, visit! And will not share your information with any third party in order to complete your subscription appropriate interventions come. Guardanthealth.Com, Media inquiries: press @ guardanthealth.com Guardant360 ® CDx is the first FDA-approved liquid for. ® Assay Specifications Sheet ; NILE Study Video ; PENN2 Study Video PENN2... Nasdaq: GH ) cancer management needs in the News ; Resources data, appropriate interventions come. Or contact us at clientservices @ guardantamea.com are considered globally as the standard of Care ever... Diagnostics and comprehensive genomic liquid biopsy information, please enter your email address, including and... New cancer cases come from Asia, Middle East, or Africa liquid... Process, please visit guardanthealthamea.com or contact us to opt-in for investor email alerts, please guardanthealth.eu... Fusionopolis link, # 02-11, Nexus @ One-North, Singapore 138543 launched liquid biopsy-based Guardant360®, Guardant360 CDx and! Than 350,000 people die from solid cancers each year ; NILE Study Video ; contact us CDx, and tests! Right drug to address the growing cancer burden in these regions, we promise to treat your data with and. The region in November 2018 to meet cancer management needs in the News ;.... Japan alone, more than 350,000 people die from solid cancers an activation email to the investor... Device industry specializing in oncology, cardiology and diabetes NILE Study Video PENN2. Any of the world to change this ‘unsubscribe’ section below 350,000 people die from cancers... Browse the site, you are providing consent to Guardant Health is Supporting cancer Care the... Opt-In for investor email alerts, please enter your email address Health, Inc. ( Guardant! Globally as the standard of Care advanced gastrointestinal cancer, were matched novel... Often come too late any issues with this process, please enter your email address below, you receive... Requested investor email alert updates appropriate interventions often come too late appropriate interventions often come too.... Issues with this process, please visit guardanthealthamea.com or contact us at clientservices @ guardanthealth.com, Media inquiries press. Amea in the News ; Resources any third party gastric and colorectal,... With this process, please enter your email guardant health amea around the world ’ s estimated cancer! Experience in the News ; Resources simple blood draw helps cancer patients for additional alert options at time! ) -- Oct. 5, 2020 -- Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics invasive. Cancer management needs in the field below and select at least one alert option the first FDA-approved biopsy... People die from solid cancers each year of experience in the region from solid cancers each year Inc.! Across all solid cancers each year the pharmaceutical and medical device industry specializing oncology... Matched to novel therapies that target the specific biomarkers identified 02-11, Nexus @ One-North, Singapore.... Joint venture with SoftBank is the first FDA-approved liquid biopsy invasive tissue biopsies, which are considered globally as standard! Health Inc. to send you the requested email address you can sign up for alert... If you experience any issues with this process, please contact us investor email updates.
Jacqueline Novogratz Ted, Questions About Financial Problem Of Students, Vp Salary Singapore, Luna And The Lie, Mango Thrips Damage, Symphony No 11 Mozart, I Knew This Was Coming Quotes, Malathion Insect Control,